ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ELV is not a clear buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has supportive analyst upgrades and insider buying, but the current technical picture is mixed and the options flow is bearish. With the price sitting just above support and no strong proprietary buy signal, I would not call this an immediate buy at current levels.
Current price is 392.82, essentially flat versus the prior close of 392.75. The trend is mixed: SMA_5 > SMA_20 > SMA_200 is bullish and shows the longer trend still intact, but the MACD histogram is -2.538 and negatively expanding, which signals weakening momentum. RSI_6 at 55.238 is neutral, so there is no overbought or oversold edge. Price is below pivot resistance at 395.384 but above S1 support at 386.331, so the stock is near a short-term decision zone rather than a strong breakout point. Overall trend: mildly constructive long-term, but short-term momentum is not strong enough to justify a decisive buy for an impatient investor.
["Recent analyst upgrades are strong, including Deutsche Bank upgrading ELV to Buy with a $498 target and Barclays raising its target to $480.", "BofA also upgraded the stock to Buy, citing confidence that Medicaid margins may bottom in 2026.", "Insiders are buying, with insider purchases rising 132.13% over the last month.", "Congress trading is slightly supportive overall, with 1 purchase and 1 sale in the last 90 days, showing neutral-to-balanced political activity.", "Longer-term moving averages remain bullish, indicating the broader uptrend is still intact."]
["No news in the recent week, so there is no fresh event-driven catalyst pushing the stock higher right now.", "Hedge funds are selling, and the selling amount increased 135.25% over the last quarter.", "MACD is negative and weakening, pointing to fading short-term momentum.", "Option volume is skewed toward puts today, which is not a strong bullish signal.", "The stock trend model suggests downside probabilities over the next week and month (-3.83% and -6.8%).", "Evercore remains cautious despite adding the name to a tactical outperform list, still citing potential Medicaid headwinds in 2027."]
The latest quarter financial snapshot was unavailable due to an error, so I cannot assess the most recent reported quarter directly. Based on the analyst commentary, Q1 appears to have been solid enough to trigger multiple target increases and upgrades, with references to durable post-Q1 moves and continued execution off a low earnings baseline. The growth narrative is more about margin recovery, Medicaid stabilization, and achievable 2026 estimates than rapid top-line acceleration.
Analyst sentiment is clearly positive and has improved recently. Multiple firms raised targets in late April and May, with upgrades from Neutral/Hold to Buy and target increases into the $435-$498 range. The Wall Street pros view is constructive: confidence in managed care, improving visibility on Medicaid margins, and durable post-Q1 momentum. The cons view is that Medicaid-related risks, exchanges, acuity, and possible 2027 headwinds remain concerns. Net: analysts are bullish overall, but the stock still has some policy and margin uncertainty embedded.
